Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Brigham and Women's Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06675695CT.gov Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases | — | Completed | — | — | — |
NCT06071013CT.gov Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | — | Recruiting | — | — | — |
NCT05834348CT.gov A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | Completed | — | — | — |
NCT04874844CT.gov JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety | — | Unknown | — | — | — |
NCT03866499CT.gov A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT04575415CT.gov Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | — | Unknown | — | — | — |
NCT04390984CT.gov Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | — | Unknown | — | — | — |
NCT04358562CT.gov Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib | — | Unknown | — | — | — |
NCT04248829CT.gov Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | — | Completed | — | — | — |
NCT04239833CT.gov A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | — | Unknown | — | — | — |
Show 127 more trialsShow fewer
NCT04179890CT.gov The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib | — | Completed | — | — | — |
NCT04143607CT.gov ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC | — | Active Not Recruiting | — | — | — |
NCT03944772CT.gov Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | — | Active Not Recruiting | — | — | — |
NCT03787992CT.gov Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG） | — | Active Not Recruiting | — | — | — |
NCT04028778CT.gov Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC | — | Unknown | — | — | — |
NCT03766490CT.gov Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03856697CT.gov Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation | — | Unknown | — | — | — |
NCT03849768CT.gov A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | — | Unknown | — | — | — |
NCT03653546CT.gov First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | — | Completed | — | — | — |
NCT03599518CT.gov DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT07271446CT.gov An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer | — | Completed | — | — | — |
NCT03656393CT.gov To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma | — | Unknown | — | — | — |
NCT03602027CT.gov Phase I Study of the Combination of Anlotinib With Gefitinib | — | Unknown | — | — | — |
NCT03529084CT.gov Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations | — | Withdrawn | — | — | — |
NCT03647592CT.gov Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03381066CT.gov A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. | — | Unknown | — | — | — |
NCT03457337CT.gov S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC | — | Unknown | — | — | — |
NCT03333343CT.gov Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | — | Active Not Recruiting | — | — | — |
NCT03267654CT.gov Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | — | Unknown | — | — | — |
NCT02856893CT.gov Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) | — | Completed | — | — | — |
NCT03264794CT.gov the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) | — | Unknown | — | — | — |
NCT03122717CT.gov Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03123484CT.gov β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC | — | Unknown | — | — | — |
NCT02976116CT.gov A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03374280CT.gov Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC | — | Unknown | — | — | — |
NCT03758287CT.gov Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative | — | Completed | — | — | — |
NCT02930954CT.gov Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | — | Unknown | — | — | — |
NCT02588261CT.gov A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | — | Terminated | — | — | — |
NCT02740894CT.gov Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ? | — | Completed | — | — | — |
NCT01951469CT.gov Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02326285CT.gov Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB | — | Terminated | — | — | — |
NCT02411448CT.gov A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) | — | Active Not Recruiting | — | — | — |
NCT02387086CT.gov Gefitinib Combined With Thalidomide to Treat NSCLC | — | Unknown | — | — | — |
NCT02374645CT.gov A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC | — | Completed | — | — | — |
NCT03399669CT.gov The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation | — | Unknown | — | — | — |
NCT02804776CT.gov PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery | — | Completed | — | — | — |
NCT02296125CT.gov AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02299765CT.gov Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT02338011CT.gov Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases) | — | Unknown | — | — | — |
NCT02179671CT.gov Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT02151721CT.gov Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer | — | Unknown | — | — | — |
NCT02148380CT.gov Combination of Chemotherapy and Gefitinib as First-line Treatment | — | Completed | — | — | — |
NCT01933347CT.gov Third-line Treatment of Gefitinib in NSCLC Patients | — | Completed | — | — | — |
NCT02088112CT.gov MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | — | Completed | — | — | — |
NCT02039674CT.gov A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | — | Completed | — | — | — |
NCT02031601CT.gov Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer | — | Unknown | — | — | — |
NCT02040064CT.gov Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients | — | Completed | — | — | — |
NCT01982955CT.gov Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | — | Completed | — | — | — |
NCT01774721CT.gov ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | — | Completed | — | — | — |
NCT01871480CT.gov CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01864681CT.gov Combination of Metformin With Gefitinib to Treat NSCLC | — | Completed | — | — | — |
NCT01833572CT.gov Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001) | — | Completed | — | — | — |
NCT01749072CT.gov Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT01755923CT.gov Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC | — | Unknown | — | — | — |
NCT01746277CT.gov Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy | — | Unknown | — | — | — |
NCT01602289CT.gov A Study of LY2875358 in Japanese Participants With Advanced Cancer | — | Completed | — | — | — |
NCT01610336CT.gov A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | — | Completed | — | — | — |
NCT01510990CT.gov First Line Gefitinib by FDG-PET Metabolic Response | — | Unknown | — | — | — |
NCT01544179CT.gov A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone | — | Completed | — | — | — |
NCT02319577CT.gov GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial | — | Unknown | — | — | — |
NCT01502202CT.gov Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers | — | Unknown | — | — | — |
NCT01469000CT.gov A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01498562CT.gov Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01570296CT.gov A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR | — | Completed | — | — | — |
NCT01405079CT.gov Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation | — | Unknown | — | — | — |
NCT01513174CT.gov Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone | — | Completed | — | — | — |
NCT01404260CT.gov Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01579630CT.gov Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy | — | Unknown | — | — | — |
NCT01203917CT.gov Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC | — | Completed | — | — | — |
NCT01312337CT.gov Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT01027676CT.gov Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) | — | Unknown | — | — | — |
NCT01039948CT.gov A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01196234CT.gov Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01192243CT.gov Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT01769066CT.gov Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC | — | Completed | — | — | — |
NCT01017874CT.gov A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00986284CT.gov Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC) | — | Suspended | — | — | — |
NCT03157310CT.gov Bone Metastasis on the Survival of Gefitinib Effective Patients | — | Completed | — | — | — |
NCT01017679CT.gov Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg | — | Completed | — | — | — |
NCT01040780CT.gov Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients | — | Completed | — | — | — |
NCT00891579CT.gov Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | — | Completed | — | — | — |
NCT00824746CT.gov Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00809237CT.gov Hydroxychloroquine and Gefitinib to Treat Lung Cancer | — | Unknown | — | — | — |
NCT00807066CT.gov Randomized Gefitinib Trial | — | Completed | — | — | — |
NCT00770588CT.gov Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01066195CT.gov Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy | — | Unknown | — | — | — |
NCT01783834CT.gov Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients | — | Completed | — | — | — |
NCT00614809CT.gov Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00536107CT.gov Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00497250CT.gov Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy | — | Unknown | — | — | — |
NCT00409006CT.gov Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers | — | Completed | — | — | — |
NCT00608868CT.gov SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients | — | Completed | — | — | — |
NCT00372515CT.gov High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations | — | Completed | — | — | — |
NCT00322452CT.gov First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia | — | Completed | — | — | — |
NCT00319800CT.gov Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC | — | Unknown | — | — | — |
NCT00090675CT.gov Maintenance ZD1839 (IRESSA®) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT01037998CT.gov UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer | — | Completed | — | — | — |
NCT00478049CT.gov Iressa as Second Line Therapy in Advanced NSCLC-Asia | — | Completed | — | — | — |
NCT00173875CT.gov Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00162318CT.gov A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00198393CT.gov Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV | — | Completed | — | — | — |
NCT00264498CT.gov Phase II Iressa & Carbo/Gem in NSCLC | — | Completed | — | — | — |
NCT00333294CT.gov Phase II Iressa + Irradiation Followed by Chemo in NSCLC | — | Completed | — | — | — |
NCT00259064CT.gov Iressa v BSC (Best Supportive Care) in First Line NSCLC | — | Completed | — | — | — |
NCT00256711CT.gov Phase II Iressa Versus Vinorelbine (INVITE) | — | Completed | — | — | — |
NCT00234442CT.gov Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00820417CT.gov Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib | — | Completed | — | — | — |
NCT00588445CT.gov Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene | — | Completed | — | — | — |
NCT00255489CT.gov A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer | — | Completed | — | — | — |
NCT00076388CT.gov Iressa Versus Docetaxel (Taxotere) | — | Completed | — | — | — |
NCT00234468CT.gov Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC | — | Terminated | — | — | — |
NCT00328562CT.gov ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00068497CT.gov Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00231465CT.gov Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00242801CT.gov Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study | — | Completed | — | — | — |
NCT00059722CT.gov This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | — | Completed | — | — | — |
NCT00049543CT.gov Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery | — | Completed | — | — | — |
NCT00048087CT.gov Iressa/Docetaxel in Non-Small-Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT00252798CT.gov ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00040794CT.gov Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00029003CT.gov Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00020709CT.gov Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00034879CT.gov Iressa Expanded Access Program (EAP) | — | Completed | — | — | — |
NCT00080340CT.gov Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00684385CT.gov An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck | — | Approved For Marketing | — | — | — |
NCT00683306CT.gov Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment | — | Approved For Marketing | — | — | — |
NCT00268255CT.gov Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gefitinib (this asset) | Brigham and Women's Hospital | Approved | BB · 69 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Gefitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Central Nervous System Neoplasm | — | P2 | BBB · 73 |
| Gliosarcoma | — | P2 | BB · 71 |
| Lung Large Cell Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gefitinib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gefitinib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →